Laura E. Pascal
YOU?
Author Swipe
View article: Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia
Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia Open
Lower urinary tract symptoms (LUTS), associated with benign prostatic hyperplasia (BPH), are an aging‐related disease, with more than 210 million cases worldwide. Estrogen exposure and estrogen regulation have been implicated in a variety …
View article: Dietary methionine restriction started late in life promotes healthy aging in a sex-specific manner
Dietary methionine restriction started late in life promotes healthy aging in a sex-specific manner Open
Aging is associated with dysregulated methionine metabolism and increased levels of enzymes in the tyrosine degradation pathway (TDP). To investigate the efficacy of targeting either methionine metabolism or the TDP for healthspan improvem…
View article: Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron‐sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain
Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron‐sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain Open
Background Benign prostatic hyperplasia (BPH) is a condition generally associated with advanced age in men that can be accompanied by bothersome lower urinary tract symptoms (LUTS) including intermittency, weak stream, straining, urgency, …
View article: Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation
Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation Open
Background Our research focused on the assessment of the impact of systemic inhibition of Trk receptors, which bind to nerve growth factor (NGF) and brain‐derived neurotrophic factor (BDNF), on bladder hypersensitivity in two distinct rode…
View article: Age-Dependent Effects of Voluntary Wheel Running Exercise on Voiding Behavior and Potential Age-Related Molecular Mechanisms in Mice
Age-Dependent Effects of Voluntary Wheel Running Exercise on Voiding Behavior and Potential Age-Related Molecular Mechanisms in Mice Open
Background Older men frequently develop lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH). Risk factors for LUTS/BPH include sedentary lifestyle, anxiety/depression, obesity, and frailty, which all increase…
View article: THU488 Genetic Alterations In CREBRF Influence Prostate Cancer Survival And Impact Prostate Tissue Homeostasis In Mice
THU488 Genetic Alterations In CREBRF Influence Prostate Cancer Survival And Impact Prostate Tissue Homeostasis In Mice Open
Disclosure: L.E. Pascal: None. K.A. Frahm: None. K. Skalitzky: None. D.B. DeFranco: None. L. Rigatti: None. R. Lu: None. T. Liu: None. Background: Risk factors for prostate cancer include age, environmental factors, race and ethnicity. Gen…
View article: Aging-Related Mitochondrial Dysfunction Is Associated With Fibrosis in Benign Prostatic Hyperplasia
Aging-Related Mitochondrial Dysfunction Is Associated With Fibrosis in Benign Prostatic Hyperplasia Open
Background Age is the greatest risk factor for lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH). Although LUTS/BPH can be managed with pharmacotherapy, treatment failure has been putatively attributed to n…
View article: Supplemental Figure S3 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S3 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S3 shows the effect of Hsp70 knockdown on AR protein level in LNCaP cells.
View article: Data from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Data from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Open
Reactivation of androgen receptor (AR) appears to be the major mechanism driving the resistance of castration-resistant prostate cancer (CRPC) to second-generation antiandrogens and involves AR overexpression, AR mutation, and/or expressio…
View article: Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Supplemental Table S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Table S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Proteins interacting with AR identified by High Accuracy Mass Spectrometer.
View article: Supplemental Figure S2 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S2 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S2 shows the co-immunoprecipitation of SBD and AR truncated mutations.
View article: Supplemental Figure S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S1 shows the Hsp70 and Hsc70 peptide sequences identified by proteomics.
View article: Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Supplemental Figure S3 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S3 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S3 shows the effect of Hsp70 knockdown on AR protein level in LNCaP cells.
View article: Data from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Data from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Open
Reactivation of androgen receptor (AR) appears to be the major mechanism driving the resistance of castration-resistant prostate cancer (CRPC) to second-generation antiandrogens and involves AR overexpression, AR mutation, and/or expressio…
View article: Supplemental Figure S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S1 shows the Hsp70 and Hsc70 peptide sequences identified by proteomics.
View article: Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Identification of novel androgen receptor (AR) antagonists may lead to urgently needed new treatments for patients with prostate cancer resistant to current AR antagonists. AR is presently the main target for treating prostate cancer. Clin…
View article: Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Supplemental Figure S4 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S4 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S4 shows the effect of 18BBQU on AR protein level in C4-2 cells.
View article: Supplemental Figure S4 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S4 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S4 shows the effect of 18BBQU on AR protein level in C4-2 cells.
View article: Supplementary Figures from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Supplementary Figures from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Open
Supplementary Figures S1-S7
View article: Data from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Data from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
The androgen receptor (AR) is a key driver and therapeutic target in androgen-sensitive prostate cancer, castration-resistant prostate cancer (CRPC), and CRPC resistant to abiraterone and enzalutamide, two second-generation inhibitors of A…
View article: Supplementary Tables from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Supplementary Tables from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Open
Supplementary Tables S1-S4
View article: Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist Open
Supplementary Figure from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
View article: Data from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Data from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
The androgen receptor (AR) is a key driver and therapeutic target in androgen-sensitive prostate cancer, castration-resistant prostate cancer (CRPC), and CRPC resistant to abiraterone and enzalutamide, two second-generation inhibitors of A…
View article: Supplementary Figures from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Supplementary Figures from A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Open
Supplementary Figures S1-S7
View article: Supplemental Table S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Table S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Proteins interacting with AR identified by High Accuracy Mass Spectrometer.
View article: Supplemental Figure S2 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Supplemental Figure S2 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells Open
Supplemental Figure S2 shows the co-immunoprecipitation of SBD and AR truncated mutations.